Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Research analysts at Svb Leerink lifted their Q1 2019 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research note issued on Thursday, April 18th. Svb Leerink analyst G. Porges now expects that the pharmaceutical company will post earnings of $0.64 per share for the quarter, up from their previous forecast of $0.57. Svb Leerink has a “Market Perform” rating on the stock.

Several other analysts have also commented on the stock. BidaskClub raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 16th. Maxim Group reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 6th. Citigroup lowered their price target on shares of Vertex Pharmaceuticals from $206.00 to $205.00 and set a “buy” rating on the stock in a research report on Friday, January 4th. Raymond James lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $165.71 price target on the stock. in a research report on Wednesday, January 2nd. Finally, Cowen reissued a “buy” rating and issued a $220.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average target price of $203.31.

Shares of VRTX stock opened at $168.16 on Friday. The stock has a market capitalization of $42.99 billion, a price-to-earnings ratio of 59.42, a P/E/G ratio of 2.67 and a beta of 1.64. Vertex Pharmaceuticals has a 52 week low of $144.07 and a 52 week high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Tuesday, February 5th. The pharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.24. The company had revenue of $870.11 million for the quarter, compared to analyst estimates of $818.29 million. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The firm’s revenue was up 33.5% on a year-over-year basis. During the same period last year, the firm earned $0.61 earnings per share.

In related news, EVP Stuart A. Arbuckle sold 5,624 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $181.75, for a total transaction of $1,022,162.00. Following the completion of the transaction, the executive vice president now owns 36,272 shares of the company’s stock, valued at $6,592,436. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP David Altshuler sold 2,125 shares of the business’s stock in a transaction that occurred on Tuesday, January 22nd. The shares were sold at an average price of $193.48, for a total transaction of $411,145.00. Following the transaction, the executive vice president now directly owns 41,238 shares of the company’s stock, valued at approximately $7,978,728.24. The disclosure for this sale can be found here. In the last three months, insiders sold 210,018 shares of company stock worth $38,398,113. Insiders own 0.75% of the company’s stock.

A number of large investors have recently modified their holdings of VRTX. Oregon Public Employees Retirement Fund grew its stake in Vertex Pharmaceuticals by 16,530.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock valued at $28,000 after acquiring an additional 4,583,156 shares in the last quarter. FMR LLC grew its stake in Vertex Pharmaceuticals by 13.3% during the fourth quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock valued at $3,394,256,000 after acquiring an additional 2,411,631 shares in the last quarter. Norges Bank purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $380,584,000. Jennison Associates LLC grew its stake in Vertex Pharmaceuticals by 11.9% during the fourth quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock valued at $1,150,296,000 after acquiring an additional 739,128 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in Vertex Pharmaceuticals by 74.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 601,559 shares of the pharmaceutical company’s stock valued at $99,685,000 after acquiring an additional 257,683 shares in the last quarter. 95.37% of the stock is owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

See Also: Why Net Income is Important to Investors

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.